Abbott at ESC 2015: Absorb Now Standing Up Against Xience, But Time To Shine Would Come Later
This article was originally published in Clinica
Executive Summary
Data from two separate clinical trials pitting Abbott’s Absorb bioresorbable heart stent against the company’s Xience everolimus drug-eluting stent have shown comparable clinical outcomes for both technologies. But these are still early days, and the real benefits of Absorb will only be known over the longer term.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.